Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. H. Cho, S. Park, H. Nam, S. Kwak, J. Ryu, H. Lee (Incheon, Seoul, Republic Of Korea). Pleural eicosanoids in patients with lung cancer. Eur Respir J 2013; 42: Suppl. 57, 3077

Member's Comments

No comment yet.

Related content which might interest you: The protein DJ-1 in malignant pleural effusions due to lung cancer: Levels and correlations with oxidative stress biomarkers Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Mucus production, lung inflammation and functional decay in IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias Source: International Congress 2014 – IPF and surroundings Year: 2014 Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions? Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Serum levels of sestrin 2 in patients with sarcoidosis Source: International Congress 2014 – ILDs 6 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Role of Dr-70 immunoassay in suspected malignant pleural effusion Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 Titel: MicroRNA analysis in Epithelial Lining Fluid (ELF) compared to Bronchoalveolar Lavage (BAL) in Interstitial pulmonary fibrosis (IPF) Source: International Congress 2014 – IPF and surroundings Year: 2014 Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Serum procalcitonin is useful in differentiating between drug-induced pneumonitis and bacterial pneumonia Source: International Congress 2014 – ILDs 5 Year: 2014 Biomarkers for interstitial lung disease Source: International Congress 2016 – ME1 Biomarkers for interstitial lung disease Year: 2016 Analysis of amylase rich pleural effusions Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer Source: International Congress 2016 – Orphan diseases I Year: 2016